All News

JIA.oligoarticular.jpg

Biologics for JIA? Not So Fast, Say Insurers

MedPage Today

It's not a simple matter to prescribe tumor necrosis factor (TNF) inhibitors for patients with juvenile idiopathic arthritis (JIA), at least those with insurance, a single-center study found.

Read Article
child.guttate.psoriasis

Kids With Psoriasis Maintained with Long Term IL-17A Inhibitor

MedPage Today

Pediatric patients with moderate-to-severe plaque psoriasis obtained significant improvement in disease status for as long as 2 years with the interleukin (IL)-17A inhibitor ixekizumab (Taltz), long-term follow-up from a randomized trial showed.

Read Article
RheumNow Podcast square

Consequences of TNF inhibition (3.18.2022)

Jack Cush, MD

This week we're going to talk about the downside of TNF inhibitors, a few interesting observations in gout, and yes, kids do get COVID. We're also going to preview what's coming in April (hint: it's about PsA). This and more as Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
RheumNow Podcast square

RheumNow Live is Coming to Town (3.11.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
Kawasaki.jpg

Kawasaki Disease Guideline from ACR and Vasculitis Foundation

ACR

The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released a new guideline for the management of Kawasaki disease that addresses diagnostic issues relating to Kawasaki disease, the treatment of high-risk patients, and the management of

Read Article
Pills.JIA_.png

ACR Guidelines for the Treatment of Systemic Juvenile Idiopathic Arthritis

Jack Cush, MD

The ACR has updated its clinical guidelines for the management of juvenile idiopathic arthritis (JIA), with this update focusing on oligoarthritis, TMJ arthritis, and systemic JIA (with and without macrophage activation syndrome); only the latter, systemic JIA recommendations are reported he

Read Article
Lupus,flare,malar,DermNetNZ

Increased SLE Flares with Hydroxychloroquine Reduction

Jack Cush, MD

Concerns about the long-term safety of hydroxychloroquine (HCQ) often results in dose reduction or drug discontinuation; yet a current study shows that, for those in remission, HCQ taper/discontinuation resulted in a significantly higher rate of SLE flares.

Read Article
RheumNow Podcast square

Diagnostic Delay in Axial Spondyloarthritis (2.25.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, rheumatologic problems incited by respiratory infections, air pollution and how you live, now where you live.

Read Article
RheumNow Podcast square

Hand OA and Heroes in Rheumatology (2.11.2022)

Jack Cush, MD

Interesting reports this week about dementia, who gets hand OA and a great list of women Heroes and Pillars of Rheumatology. Tune in as Dr. Jack Cush reviews the news and journal articles from this past week in RheumNow.com.

Read Article
coronavirus,COVID,MISC,mask

ACR Updates Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With COVID

Jack Cush, MD

A Task Force from the ACR has provided an updated (version 3) guidance for the diagnosis and management of Multisystem Inflammatory Syndrome in Children (MIS-C), a COVID related condition characterized by fever, inflammation, and multiorgan dysfunction.

Read Article
FDA approved 1st drug for kids with COVID-19. Veklury (remdesivir) get an expanded indication in Peds >28days old & wt > 3 kg who has SARS-CoV-2 & are Hospitalized, or Not hospitalized & at high risk for severe COVID-19 or death https://t.co/7Hn4CwKjxv

Links:

Dr. John Cush RheumNow ( View Tweet)

Italian retrospective of Canakinumab in 80 kids w/ Systemic JIA - 12 moved from anakinra to CAN w/ iinactive dz/CID. 58 pts w/ active SoJIA started CAN - CID in 57% at 6mos, 64% 12 mos; MAS 3/100PY; Nonresp assoc w/ MAS, #Jts, Dz duration https://t.co/2YmkukU7Z2

Links:

Dr. John Cush RheumNow ( View Tweet)

Your Hot Topic Questions from RNL 2022 Rheumatologists questions for Dr. Jack Cush QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/wpPeIwiCxe https://t.co/UY3gDaVeTv

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective cohort hospital study of 228 children with MIS-C; 215 patients (median age 8 yrs, 63% boys) shows that orticosteroid monotherapy is a reasonable management option for a subset of patients with MIS-C, particularly those with mild disease https://t.co/HLSR5zOseU https://t.co/5z7I9SVcxI

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Jonathan Hausman on JIA Most subjects equivalent to adult forms of inflammatory arthritis - note early onset seronegative oligoarthritis Tips on transitioning to adult care - determine extent of active disease vs. chronic damage @RheumNow #RNL2022 https://t.co/MhjH04PQ3e
Robert B Chao, MD doctorRBC ( View Tweet)
ILAR classifications vs the reality of disease changes seen in pedi clinics is an issue for continuing care. Dr. @hausmannMD reviews arthritis clusters which may make it easier to understand from an adult rheum perspective. #RNL2022 @RheumNow https://t.co/7xYD96R5Rw
Dr. Rachel Tate uptoTate ( View Tweet)
ICYMI: Kawasaki Disease Guideline from ACR and Vasculitis Foundation https://t.co/ixKL6juqkM https://t.co/Nw4yi0OZPy

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Guidelines for the Treatment of Systemic Juvenile Idiopathic Arthritis The ACR has updated its clinical guidelines for the management of JIA, with this update focusing on oligoarthritis, TMJ arthritis, and systemic JIA. https://t.co/eKv8qubl1v https://t.co/xLBMccCYex

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective study of juvenile dermatomyositis shows 1st line Rx w/ MTX is not effective, esp in MSA Ab+ pts. 45 JDM pts (2/3 severe) Rx w/ 6 mos MTX + steroids; inactive dz seen in 31%, with 42% muscle and 33% skin responses. MSA neg pts did better https://t.co/PDubjbcMe2 https://t.co/rGCSZ3ZT9U

Links:

Dr. John Cush RheumNow ( View Tweet)
CARRA Registry looked at TNFi use in JIA and found a nearly 3 fold increased risk of psoriasis. 8225 pts w/ 3.9 yrs of F/U. 54% recv TNFi; the aHR of new onset of psoriasis after TNFi exposure was 2.93 (2.15 to 3.98). MTX had lower risk (HR 0.45) https://t.co/Z6qvlS26M9

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×